Tandem Diabetes Care Stock (NASDAQ: TNDM)

Tandem Diabetes Care (NASDAQ:TNDM) Stock, Quote.Headers.trade-ideas

Tandem Diabetes Care

Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on a tubeless pump. Nearly three-quarters of total revenue is derived from the us, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days.

Crude-oil-4-logo

Earnings

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

BIAF

GPAK

TNDM

VINE

VSEE

XCUR

Crude Oil Falls Sharply; Exxon Mobil Earnings Top Views

jobs ai

Nasdaq Tumbles 3%; US Economy Adds 114,000 Jobs In July

wall-street-ai17

Movers

BFAM

CERS

DASH

EZPW

FTEL

GDDY

ICFI

MELI

WLDN

MercadoLibre Posts Upbeat Results, Joins Integral Ad Science, Willdan Group, Fresh Del Monte Produce And Other Big Stocks Moving Higher On Friday

Tandem Diabetes Care, Inc. - Common Stock

Tandem Diabetes Care Inc

Biotech

General

Tandem's t:slim X2 Insulin Pump Now Compatible With Lyumjev Ultra-Rapid Acting Insulin In The European Union

Morgan Stanley analyst Patrick Wood initiates coverage on Tandem Diabetes Care (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) with a Equal-Weight rating and announces Price Target of $45.

Price Target

Initiation

Analyst Ratings

Morgan Stanley Initiates Coverage On Tandem Diabetes Care with Equal-Weight Rating, Announces Price Target of $45

Tandem Diabetes Care, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) today announced the planned release of version 2.8.2 of its Apple iOS t:connect mobile app in the United States on August 20, 2024 to correct an issue described in a March 2024 recall that can cause rapid depletion of a user's t:slim X2 insulin pump battery. This battery depletion can result in the pump shutting down sooner than expected, which some customers have continued to see following the release of version 2.7.1 of the app in March. Tandem encourages all impacted t:slim X2 iOS users to update their mobile app as soon as the new version is available in the Apple App Store.
Under-delivery of insulin because of a pump shutdown can result in hyperglycemia or diabetic ketoacidosis, which can be a life-threatening condition due to high blood sugar and lack of insulin. There have been 143 confirmed adverse events with this recall. Adverse events are defined as a confirmed high blood sugar and/or an event requiring medical intervention. Two hospitalizations and no deaths have been reported.

AAPL

Tandem Diabetes Care Urges iOS Users to Update App to Prevent Insulin Pump Battery Issues

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>VERV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$5.00</td>
<td>$121.2K</td>
<td>22</td>
<td>1.0K</td>
</tr>
<tr>
<td>GSK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$41.00</td>
<td>$28.0K</td>
<td>1.8K</td>
<td>913</td>
</tr>
<tr>
<td>CLOV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$2.00</td>
<td>$46.2K</td>
<td>7.3K</td>
<td>550</td>
</tr>
<tr>
<td>CRBP</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$50.00</td>
<td>$39.1K</td>
<td>1.5K</td>
<td>183</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$900.00</td>
<td>$56.1K</td>
<td>784</td>
<td>142</td>
</tr>
<tr>
<td>ADMA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$17.50</td>
<td>$28.0K</td>
<td>3.4K</td>
<td>117</td>
</tr>
<tr>
<td>TNDM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$45.00</td>
<td>$26.4K</td>
<td>10</td>
<td>100</td>
</tr>
<tr>
<td>AZN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$80.00</td>
<td>$32.0K</td>
<td>1.0K</td>
<td>52</td>
</tr>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$72.50</td>
<td>$61.5K</td>
<td>8</td>
<td>46</td>
</tr>
<tr>
<td>ELV</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$550.00</td>
<td>$26.4K</td>
<td>184</td>
<td>26</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• Regarding VERV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERV#NASDAQ">VERV</a>), we observe a put option sweep with bullish sentiment. It expires in 186 day(s) on February 21, 2025. Parties traded 1000 contract(s) at a $5.00 strike. This particular put needed to be split into 15 different trades to become filled. The total cost received by the writing party (or parties) was $121.2K, with a price of $120.0 per contract. There were 22 open contracts at this strike prior to today, and today 1005 contract(s) were bought and sold. 
• Regarding GSK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>), we observe a call option sweep with bearish sentiment. It expires in 32 day(s) on September 20, 2024. Parties traded 200 contract(s) at a $41.00 strike. This particular call needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $28.0K, with a price of $140.0 per contract. There were 1865 open contracts at this strike prior to today, and today 913 contract(s) were bought and sold. 
• For CLOV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLOV#NASDAQ">CLOV</a>), we notice a call option sweep that happens to be bearish, expiring in 151 day(s) on January 17, 2025. This event was a transfer of 350 contract(s) at a $2.00 strike. This particular call needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $46.2K, with a price of $132.0 per contract. There were 7304 open contracts at this strike prior to today, and today 550 contract(s) were bought and sold. 
• For CRBP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBP#NASDAQ">CRBP</a>), we notice a put option sweep that happens to be bullish, expiring in 60 day(s) on October 18, 2024. This event was a transfer of 38 contract(s) at a $50.00 strike. This particular put needed to be split into 9 different trades to become filled. The total cost received by the writing party (or parties) was $39.1K, with a price of $1030.0 per contract. There were 1500 open contracts at this strike prior to today, and today 183 contract(s) were bought and sold. 
• For LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we notice a call option trade that happens to be bearish, expiring in 60 day(s) on October 18, 2024. This event was a transfer of 10 contract(s) at a $900.00 strike. The total cost received by the writing party (or parties) was $56.1K, with a price of $5617.0 per contract. There were 784 open contracts at this strike prior to today, and today 142 contract(s) were bought and sold. 
• For ADMA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>), we notice a call option trade that happens to be bullish, expiring in 151 day(s) on January 17, 2025. This event was a transfer of 100 contract(s) at a $17.50 strike. The total cost received by the writing party (or parties) was $28.0K, with a price of $280.0 per contract. There were 3492 open contracts at this strike prior to today, and today 117 contract(s) were bought and sold. 
• For TNDM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>), we notice a put option sweep that happens to be bearish, expiring in 32 day(s) on September 20, 2024. This event was a transfer of 98 contract(s) at a $45.00 strike. This particular put needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $26.4K, with a price of $270.0 per contract. There were 10 open contracts at this strike prior to today, and today 100 contract(s) were bought and sold. 
• For AZN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>), we notice a call option trade that happens to be bearish, expiring in 60 day(s) on October 18, 2024. This event was a transfer of 50 contract(s) at a $80.00 strike. The total cost received by the writing party (or parties) was $32.0K, with a price of $640.0 per contract. There were 1099 open contracts at this strike prior to today, and today 52 contract(s) were bought and sold. 
• For CVS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), we notice a put option sweep that happens to be bullish, expiring in 214 day(s) on March 21, 2025. This event was a transfer of 42 contract(s) at a $72.50 strike. This particular put needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $61.5K, with a price of $1465.0 per contract. There were 8 open contracts at this strike prior to today, and today 46 contract(s) were bought and sold. 
• For ELV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>), we notice a put option trade that happens to be bearish, expiring in 32 day(s) on September 20, 2024. This event was a transfer of 20 contract(s) at a $550.00 strike. The total cost received by the writing party (or parties) was $26.4K, with a price of $1320.0 per contract. There were 184 open contracts at this strike prior to today, and today 26 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

ADMA

CLOV

CRBP

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

VERV

10 Health Care Stocks Whale Activity In Today's Session

This battery depletion can result in the pump shutting down sooner than expected, which some customers have continued to experience following the release of version 2.7.1 of the app in March.
Notices were emailed to impacted customers on August 9, 2024 with updated information and recommendations for helping avoid pump battery depletion.
Tandem plans to release a new version of the app to address the remaining issues and will notify all users by email and app push notifications following its release.
Under-delivery of insulin because of a pump shutdown can result in hyperglycemia or diabetic ketoacidosis, which can be a life-threatening condition due to high blood sugar and lack of insulin.&nbsp;here have been 107 confirmed adverse events with this recall. Adverse events are defined as a confirmed high blood sugar and/or an event requiring medical intervention. Two hospitalizations and no deaths have been reported.

Tandem Diabetes Care Update On March Recall Of t:connect Mobile App For iOS Devices; Says Under-delivery Of Insulin Because Of Pump Shutdown Can Be Life-threatening Condition

Tandem Diabetes Care (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) underwent analysis by 11 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Tandem Diabetes Care, presenting an average target of $57.18, a high estimate of $75.00, and a low estimate of $39.00. This upward trend is evident, with the current average reflecting a 17.49% increase from the previous average price target of $48.67.
<img src="https://www.benzinga.com/files/images/story/2024/1723132839_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The standing of Tandem Diabetes Care among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Announces</td>
<td>Buy</td>
<td>$57.00</td>
<td>-</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$58.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$55.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Jeff Johnson</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$39.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$55.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Steven Lichtman</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$58.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Issie Kirby</td>
<td>Redburn Atlantic</td>
<td>Announces</td>
<td>Buy</td>
<td>$60.00</td>
<td>-</td>
</tr>
<tr>
<td>Mathew Blackman</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$60.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Brooks O'Neil</td>
<td>Lake Street</td>
<td>Raises</td>
<td>Buy</td>
<td>$75.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$57.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Mathew Blackman</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$55.00</td>
<td>$45.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Tandem Diabetes Care. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Tandem Diabetes Care compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Tandem Diabetes Care's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Tandem Diabetes Care's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/TNDM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Tandem Diabetes Care analyst ratings.</a>
<h2>All You Need to Know About Tandem Diabetes Care</h2>
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on a tubeless pump. Nearly three-quarters of total revenue is derived from the us, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days.
<h3>Tandem Diabetes Care's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Tandem Diabetes Care displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 13.27%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Tandem Diabetes Care's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -13.89%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Tandem Diabetes Care's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -12.92%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -3.28%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Tandem Diabetes Care's debt-to-equity ratio is below the industry average at 2.04, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: What Are They?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Critical Insights From Tandem Diabetes Care Analyst Ratings: What You Need To Know

Canaccord Genuity analyst William Plovanic initiates coverage on Tandem Diabetes Care (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) with a Buy rating and announces Price Target of $57.

Canaccord Genuity Initiates Coverage On Tandem Diabetes Care with Buy Rating, Announces Price Target of $57

WIIM

Tandem Diabetes Care shares are trading higher. The company last week reported better-than-expected Q2 earnings and issued strong guidance.

Barclays analyst Matt Miksic maintains Tandem Diabetes Care (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) with a Overweight and raises the price target from $55 to $58.

Barclays Maintains Overweight on Tandem Diabetes Care, Raises Price Target to $58

U.S. stocks traded lower toward the end of trading, with the S&amp;P 500 falling more than 2% on Friday.
The Dow traded down 1.92% to 39,571.38 while the NASDAQ fell 2.56% to 16,754.04. The S&amp;P 500 also fell, dropping, 2.15% to 5,329.56.
Leading and Lagging Sectors Consumer staples shares rose by 0.3% on Friday.
In trading on Thursday, consumer discretionary shares dipped by 5.4%.
Top Headline
 Exxon Mobil Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) reported better-than-expected second-quarter FY24 results on Friday.
Total revenues and other income stood at $93.060 billion, beating the consensus of $90.987 billion. Adjusted net profit came in at $9.24 billion, up from $8.22 billion in the prior quarter. Adjusted EPS stood at $2.14, beating the consensus of $2.01.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>VSee Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSEE#NASDAQ">VSEE</a>) shares shot up 100% to $4.85 after the company announced an agreement with Ava Robotics to develop telepresence solutions for the inpatient intensive care market.</li>
<li>Shares of Exicure, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) got a boost, surging 37% to $0.6790&nbsp;after the company announced it received a continued listing determination from the Nasdaq.</li>
<li>Tandem Diabetes Care, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) shares were also up, gaining 18% to $41.56 following better-than-expected second-quarter earnings and strong guidance.</li>
</ul>
Equities Trading DOWN
<ul>
<li>bioAffinity Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIAF#NASDAQ">BIAF</a>) shares dropped 29% to $1.68 after the company announced pricing of registered direct offering and concurrent private placement and warrant inducement for aggregate gross proceeds of $1.75 million.</li>
<li>Shares of Gamer Pakistan Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GPAK#NASDAQ">GPAK</a>) were down 50% to $0.0845 after the company announced it received a delisting notice from the Nasdaq.</li>
<li>Fresh Vine Wine, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VINE#NASDAQ">VINE</a>) was down, falling 30% to $0.3051 after the company announced that it terminated the merger agreement with Notes Live.</li>
</ul>
Commodities In commodity news, oil traded down 3.9% to $73.37 while gold traded down 0.4% at $2,470.30.
Silver traded down 0.3% to $28.40 on Friday, while copper rose 0.6% to $4.1050.
Euro zone
European shares closed lower today. The eurozone's STOXX 600 fell 2.73%, Germany's DAX fell 2.33% and France's CAC 40 fell 1.61%. Spain's IBEX 35 Index fell 1.67%, while London's FTSE 100 fell 1.31%.
Asia Pacific Markets
Asian markets closed lower on Friday, with Japan's Nikkei 225 dipping 5.81%, Hong Kong's Hang Seng Index falling 2.08%, China's Shanghai Composite Index falling 0.92% and S&amp;P BSE Sensex declining 1.08%.
Economics
<ul>
<li>Nonfarm payrolls came in at 114,000 last month, a slowdown of 65,000 from June, and well below the economist consensus estimate of 175,000 according to TradingEconomics.</li>
<li>The unemployment rate rose from 4.1% to 4.3%, contrary to expectations of it remaining unchanged.</li>
<li>Wage growth showed further signs of cooling, with average hourly earnings rising by 0.2% month-over-month, down from 0.3% in June and slightly below expectations.</li>
<li>U.S. factory orders declined by 3.3% from the prior month to $564.2 billion in June compared to market estimates of a 2.9% drop.</li>
<li>The total number of active U.S. oil rigs were unchanged at 482 rigs this week, Baker Hughes Inc reported.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/08/40122820/amazon-apple-and-3-stocks-to-watch-heading-into-friday"> Amazon, Apple And 3 Stocks To Watch Heading Into Friday</a></li>
</ul>

Wells Fargo analyst Larry Biegelsen maintains Tandem Diabetes Care (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) with a Overweight and raises the price target from $50 to $55.

Wells Fargo Maintains Overweight on Tandem Diabetes Care, Raises Price Target to $55

U.S. stocks traded lower midway through trading, with the Nasdaq Composite dipping more than 500 points on Friday.
The Dow traded down 2.26% to 39,435.67 while the NASDAQ fell 2.98% to 16,682.31. The S&amp;P 500 also fell, dropping, 2.52% to 5,309.54.
Leading and Lagging Sectors Real estate shares fell by just 0.5% on Friday.
In trading on Thursday, consumer discretionary shares dipped by 5.7%.
Top Headline Nonfarm payrolls came in at 114,000 last month, a slowdown of 65,000 from June, and well below the economist consensus estimate of 175,000 according to TradingEconomics.
The unemployment rate rose from 4.1% to 4.3%, contrary to expectations of it remaining unchanged.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>VSee Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSEE#NASDAQ">VSEE</a>) shares shot up 116% to $5.24 after the company announced an agreement with Ava Robotics to develop telepresence solutions for the inpatient intensive care market.</li>
<li>Shares of Exicure, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) got a boost, surging 35% to $0.6699&nbsp;after the company announced it received a continued listing determination from the Nasdaq.</li>
<li>Tandem Diabetes Care, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) shares were also up, gaining 17% to $41.30 following better-than-expected second-quarter earnings and strong guidance.</li>
</ul>
Equities Trading DOWN
<ul>
<li>bioAffinity Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIAF#NASDAQ">BIAF</a>) shares dropped 31% to $1.6350 after the company announced pricing of registered direct offering and concurrent private placement and warrant inducement for aggregate gross proceeds of $1.75 million.</li>
<li>Shares of Gamer Pakistan Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GPAK#NASDAQ">GPAK</a>) were down 46% to $0.0899 after the company announced it received a delisting notice from the Nasdaq.</li>
<li>Fresh Vine Wine, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VINE#NASDAQ">VINE</a>) was down, falling 38% to $0.27 after the company announced that it terminated the merger agreement with Notes Live.</li>
</ul>
Commodities In commodity news, oil traded down 3.6% to $73.57 while gold traded down 0.2% at $2,477.10.
Silver traded down 0.8% to $28.26 on Friday, while copper rose 0.7% to $4.1095.
Euro zone
European shares were lower today. The eurozone's STOXX 600 fell 2.75%, Germany's DAX fell 2.32% and France's CAC 40 fell 1.52%. Spain's IBEX 35 Index fell 1.62%, while London's FTSE 100 fell 1.32%.
Asia Pacific Markets
Asian markets closed lower on Friday, with Japan's Nikkei 225 dipping 5.81%, Hong Kong's Hang Seng Index falling 2.08%, China's Shanghai Composite Index falling 0.92% and S&amp;P BSE Sensex declining 1.08%.
Economics
<ul>
<li>Nonfarm payrolls came in at 114,000 last month, a slowdown of 65,000 from June, and well below the economist consensus estimate of 175,000 according to TradingEconomics.</li>
<li>The unemployment rate rose from 4.1% to 4.3%, contrary to expectations of it remaining unchanged.</li>
<li>Wage growth showed further signs of cooling, with average hourly earnings rising by 0.2% month-over-month, down from 0.3% in June and slightly below expectations.</li>
<li>U.S. factory orders declined by 3.3% from the prior month to $564.2 billion in June compared to market estimates of a 2.9% drop.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/08/40122820/amazon-apple-and-3-stocks-to-watch-heading-into-friday">Amazon, Apple And 3 Stocks To Watch Heading Into Friday</a>

U.S. stocks were lower, with the Dow Jones index falling over 900 points on Friday.
Shares of MercadoLibre, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MELI#NASDAQ">MELI</a>) rose sharply during Friday's session after the company reported better-than-expected quarterly financial results.
Mercado Libre reported net revenue of $5.07 billion in the second quarter, up 42% year-over-year. The revenue beat a Street consensus estimate of $4.68 billion, according to data from Benzinga Pro.
The company reported a 36% year-over-year increase in total payment volume for the second quarter and a 20% year-over-year rise in gross merchandise volume. Earnings per share were $10.48 in the second quarter, beating a Street consensus estimate of $8.43.
MercadoLibre shares jumped 9.6% to $1,760.79 on Friday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Fitell Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTEL#NASDAQ">FTEL</a>) gained 26% to $24.50.</li>
<li>Tandem Diabetes Care, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) shares surged 23.6% to $43.52 in pre-market trading following better-than-expected second-quarter earnings and strong guidance.</li>
<li>Cerus Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERS#NASDAQ">CERS</a>) gained 23% to $2.5200  after the company reported better-than-expected second-quarter EPS results and raised its FY24 product revenue guidance above estimates..</li>
<li>Integral Ad Science Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IAS#NASDAQ">IAS</a>) shares gained 14.9% to $11.38 after the company reported better-than-expected quarterly financial results and issued FY24 revenue guidance above estimates.</li>
<li>Willdan Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLDN#NASDAQ">WLDN</a>) climbed 10.1% to $36.52 after the company reported better-than-expected second-quarter financial results.</li>
<li>Fresh Del Monte Produce Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDP#NYSE">FDP</a>) gained 8.6% to $26.73 following better-than-expected earnings.</li>
<li>ICF International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICFI#NASDAQ">ICFI</a>) rose 8.3% to $158.06 following upbeat quarterly results.</li>
<li>EZCORP, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EZPW#NASDAQ">EZPW</a>) jumped 8.2% to $11.35.</li>
<li>Standard BioTools Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAB#NYSE">LAB</a>) gained 7.7% to $1.530.</li>
<li>Bright Horizons Family Solutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFAM#NYSE">BFAM</a>) gained 7.5% to $127.32 following strong quarterly results.</li>
<li>DoorDash, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>) rose 6.7% to $115.52 as the company posted upbeat earnings.</li>
<li>GoDaddy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GDDY#NYSE">GDDY</a>) jumped 5.8% to $149.66 after the company reported better-than-expected second-quarter sales results..</li>
<li>The Clorox Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) gained 4.3% to $139.94 after the company reported better-than-expected fourth-quarter adjusted EPS results and issued FY24 adjusted EPS guidance above estimates.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/08/40131885/dow-dips-over-400-points-apple-posts-upbeat-earnings">Dow Dips Over 400 Points; Apple Posts Upbeat Earnings</a></li>
</ul>

Baird analyst Jeff Johnson maintains Tandem Diabetes Care (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) with a Neutral and raises the price target from $36 to $39.

Baird Maintains Neutral on Tandem Diabetes Care, Raises Price Target to $39

Piper Sandler analyst Matt O'Brien reiterates Tandem Diabetes Care (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) with a Overweight and raises the price target from $50 to $55.

Reiteration

Piper Sandler Reiterates Overweight on Tandem Diabetes Care, Raises Price Target to $55

Shares of DoorDash, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>) rose sharply in today's pre-market trading after the company reported better-than-expected <a href="https://www.benzinga.com/news/earnings/24/08/40116158/doordash-q2-earnings-revenue-beat-eps-miss-total-orders-up-19-results-reflect-years-of-investment-a">second-quarter revenue results</a>.
DoorDash reported second-quarter revenue of $2.63 billion, beating the consensus estimate of $2.54 billion, according to Benzinga Pro. The company reported a quarterly loss of 38 cents per share, missing analyst estimates for a loss of 9 cents per share.
DoorDash shares jumped 10% to $118.88 in pre-market trading.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>VSee Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSEE#NASDAQ">VSEE</a>) gained 123.4% to $5.43 in pre-market trading after the company announced an agreement with Ava Robotics to develop telepresence solutions for the inpatient intensive care market.</li>
<li>Akanda Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKAN#NASDAQ">AKAN</a>) gained 34.5% to $1.95 in pre-market trading after declining 3% on Thursday.</li>
<li>Exicure, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) rose 27.3% to $0.6301 in today's pre-market trading  after the company announced it received a continued listing determination from the Nasdaq.</li>
<li>Tandem Diabetes Care, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) jumped 25% to $44.00 in pre-market trading  following better-than-expected second-quarter earnings and strong guidance.</li>
<li>OS Therapies Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSTX#NASDAQ">OSTX</a>) shares gained 22.3% to $3.07 in pre-market trading after dipping 37% on Thursday. OS Therapies reported the pricing of its IPO of 1.60 million shares at $4.00 per share.</li>
<li>Heramba Electric plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PITA#NASDAQ">PITA</a>) shares gained 17.3% to $4.47 in pre-market trading after dipping around 18% on Thursday.</li>
<li>Vaccinex, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCNX#NASDAQ">VCNX</a>) shares gained 16.8% to $5.68 in pre-market trading. The company recently announced results of its early stage SIGNAL-AD clinical trial of pepinemab antibody in AD.</li>
<li>Integral Ad Science Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IAS#NASDAQ">IAS</a>) shares rose 12.9% to $11.20 in pre-market trading after the company reported better-than-expected quarterly financial results and issued FY24 revenue guidance above estimates.</li>
<li>MercadoLibre, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MELI#NASDAQ">MELI</a>) shares rose 9.1% to $1,751.21 in pre-market trading after the company reported better-than-expected quarterly financial results.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Gamer Pakistan Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GPAK#NASDAQ">GPAK</a>) shares fell 39.2% to $0.1021 in pre-market trading after the company announced it received a delisting notice from the Nasdaq.</li>
<li>Fresh Vine Wine, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VINE#NASDAQ">VINE</a>) shares dipped 37.5% to $0.2730 in pre-market trading after the company announced that it terminated the merger agreement with Notes Live.</li>
<li>Intel Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) fell 21.9% to $22.72 in pre-market trading after the company reported its second-quarter financial results Thursday.</li>
<li>Procore Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PCOR#NYSE">PCOR</a>) shares declined 21.9% to $52.48 in pre-market trading after the company reported second-quarter financial results and issued third-quarter revenue guidance below estimates.</li>
<li>Snap Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>) fell 17.1% to $10.62 pre-market trading after the company reported mixed second-quarter financial results.</li>
<li>Atlassian Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>) shares declined 16.9% to $143.94 in pre-market trading after the company posted fourth-quarter results.</li>
<li>Opendoor Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPEN#NASDAQ">OPEN</a>) shares fell 11.7% to $1.88 in pre-market trading after the company reported second-quarter financial results.</li>
<li>Lexicon Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>) dipped 10.9% to $1.80 in pre-market trading after the company posted weak second-quarter results.</li>
<li>Mitsubishi UFJ Financial Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MUFG#NYSE">MUFG</a>) shares declined 8.5% to $10.11 in pre-market trading.</li>
<li>Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) shares fell 8.4% to $168.63 in pre-market trading as the company posted mixed results for its second quarter on Thursday.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/08/40118500/nvidia-maplebear-and-two-other-stocks-insiders-are-selling">NVIDIA, Maplebear And Two Other Stocks Insiders Are Selling</a></li>
</ul>

Pre-Market Outlook

AKAN

AMZN

INTC

LXRX

MUFG

OPEN

OSTX

PCOR

PITA

SNAP

TEAM

VCNX

Why DoorDash Shares Are Trading Higher By 10%; Here Are 20 Stocks Moving Premarket

Tandem Diabetes Care shares are trading higher following better-than-expected Q2 earnings and strong guidance.

Guidance

Tandem Diabetes Care Sees Q3 Revenue $222M-$225M Vs $204.902M Est.

Tandem Diabetes Care Sees FY24 Revenue $885M-$892M Vs $869.843M Est.

William Plovanic, an analyst from Canaccord Genuity, has initiated a new Buy rating on Tandem Diabetes Care (TNDM). William Plovanic has given his ...

Tandem Diabetes Care: A Strong Buy on Market Positioning and Growth Prospects

Canaccord Genuity analyst William Plovanic maintained a Buy rating on Tandem Diabetes Care (TNDM – Research Report) yesterday and set a price targe...

Tandem Diabetes Care: A Strong Buy on Robust Growth and Promising Future Catalysts

Tandem Diabetes: Mobi's Surprise Sales Fail To Offset Flat Operating Margin

Lake Street Sticks to Its Buy Rating for Tandem Diabetes Care (TNDM)

Tandem Diabetes a new equal weight at Morgan Stanley due to competition

In a report released today, Mathew Blackman from Stifel Nicolaus maintained a Buy rating on Tandem Diabetes Care (TNDM – Research Report), with a p...

Stifel Nicolaus Sticks to Its Buy Rating for Tandem Diabetes Care (TNDM)

Embecta gets FDA clearance for type 2 diabetes patch pump

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Sanofi (SNYNF – Research Report) and Tandem Diabet...

Analysts Conflicted on These Healthcare Names: Sanofi (OtherSNYNF) and Tandem Diabetes Care (TNDM)

Three 'buys,' three 'sells,' and a 'hold,' by Oppenheimer analysts

Tandem Diabetes rises as insulin pump cleared for use in EU with Lilly insulin

DXCM

EMBC

PODD

RXST

SNYNF

Press Releases

Tandem Mobi Improves Quality of Life for People Living With Type 1 Diabetes in New Data Shared at American Diabetes Association Scientific Sessions

Tandem Diabetes Care to Announce Second Quarter 2024 Financial Results on August 1, 2024

Tandem Diabetes Care and Dexcom Announce the t:slim X2 Insulin Pump with Dexcom G7 CGM Compatibility is Authorized for Sale by Health Canada

Tandem Diabetes Care Announces Upcoming Conference Presentation

Tandem Diabetes Care Announces Second Quarter 2024 Financial Results and Increases Full Year 2024 Sales Guidance

Legal

TANDEM ALERT: Bragar Eagel & Squire, P.C. is Investigating Tandem Diabetes Care, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Tandem Diabetes Care Provides Update on March 2024 Nationwide Recall of t:connect Mobile App for iOS Devices

Tandem Diabetes Care to Release Updated iOS t:connect Mobile App for t:slim X2 Insulin Pump Users Impacted by March 2024 Nationwide Recall

Tandem Diabetes Care Announces Upcoming Conference Participation

Tandem t:slim X2 Insulin Pump Now Compatible with Lyumjev Ultra-rapid Acting Insulin in European Union

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Tandem Diabetes Care

Tandem Diabetes Care (TNDM) Forecast

Tandem Diabetes Care (NASDAQ:TNDM) Stock, Quote.Headers.trade-ideas